Maria Arroz

ORCID: 0000-0002-7648-3294
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Immunodeficiency and Autoimmune Disorders
  • HIV Research and Treatment
  • Cytomegalovirus and herpesvirus research
  • Immune Cell Function and Interaction
  • Cancer Genomics and Diagnostics
  • Protein Degradation and Inhibitors
  • Cancer Cells and Metastasis
  • Ocular Diseases and Behçet’s Syndrome
  • Single-cell and spatial transcriptomics
  • Calcium signaling and nucleotide metabolism
  • Ecology and Conservation Studies
  • T-cell and B-cell Immunology
  • Systemic Lupus Erythematosus Research
  • Advanced Breast Cancer Therapies
  • Colorectal Cancer Screening and Detection
  • Esophageal Cancer Research and Treatment
  • Entomological Studies and Ecology
  • Herpesvirus Infections and Treatments
  • Radiomics and Machine Learning in Medical Imaging
  • Polyomavirus and related diseases
  • Lung Cancer Research Studies
  • Viral-associated cancers and disorders

Centro Hospitalar de Lisboa Ocidental
2014-2023

Hospital of St. Francis Xavier
2010-2020

Hudson Institute
2019

Massachusetts General Hospital
2019

John Wiley & Sons (United States)
2019

Istituto Nazionale di Fisica Nucleare, Sezione di Milano
2018

Universidade Nova de Lisboa
2009

Hospital de Egas Moniz
2002-2007

Nova Medical (United States)
2001-2006

Fundação para a Ciência e Tecnologia
2002

Immunophenotyping by flow cytometry has become standard practice in the evaluation and monitoring of patients with hematopoietic neoplasia. However, despite its widespread use, considerable variability continues to exist reagents used for format which results are reported. As part 2006 Bethesda Consensus conference, a committee was formed attempt define consensus set suitable general use diagnosis neoplasms. The included laboratory professionals from private, public, university hospitals as...

10.1002/cyto.b.20363 article EN Cytometry Part B Clinical Cytometry 2007-01-01

The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility there is no consensus the role of new markers. aim this project was to identify reproducible markers recommended diagnosis CLL. ERIC/ESCCA members classified 14 35 potential as “required” or “recommended” diagnosis, being defined >75% >50% agreement, respectively. An approach validate using normal peripheral blood developed. Responses were received from...

10.1002/cyto.b.21595 article EN cc-by-nc Cytometry Part B Clinical Cytometry 2017-10-10

Background Major heterogeneity between laboratories in flow cytometry (FC) minimal residual disease (MRD) testing multiple myeloma (MM) must be overcome. Cytometry societies such as the International Clinical Society and European for Cell Analysis recognize a strong need to establish minimally acceptable requirements recommendations perform complex testing. Methods A group of 11 cytometrists currently performing FC MM using different instrumentation, panel designs (≥ 6‐color) analysis...

10.1002/cyto.b.21228 article EN Cytometry Part B Clinical Cytometry 2015-01-24

Malignant epithelial cells may be detected in different specimens, by immunophenotyping using flow cytometry (FCM). CD326 (epithelial-specific antigen, clone Ber-Ep4) was used to identify cells, CD45 discriminate between leucocytes (positive for this antigen) and non-hematological (negative antigen), CD33 monocytes/macrophages. This combination is particularly useful effusions characterize large distinguish monocyte/macrophages (CD45+ CD33+ CD326-), mesothelial (CD45 ± (dim) - CD326-) +). We...

10.1002/cyto.b.21258 article EN Cytometry Part B Clinical Cytometry 2015-06-06

Torque teno virus (TTV) was recently identified as a potential biomarker for the degree of immunosuppression, and potentially predictor rejection infection in solid organ transplant patients. We evaluated TTV viral load kidney (KT) patients during first year post-transplant to examine overall kinetics their relationships with deleterious events, including episodes formation de novo donor-specific antibodies (DSAs). In single-center, prospective observational cohort study, 81 KT were...

10.3390/v15071464 article EN cc-by Viruses 2023-06-28

Abstract Background Multiple myeloma (MM) measurable residual disease (MRD) evaluated by flow cytometry is a surrogate for progression‐free and overall survival in clinical trials. However, analysis reporting between centers lack uniformity. We designed consensus protocol MM MRD to reduce inter‐laboratory variation reporting. Methods Seventeen participants from 13 countries performed blinded of the same eight de‐identified files patients with/without using their own method (Stage 1). A...

10.1002/cyto.b.22053 article EN Cytometry Part B Clinical Cytometry 2022-01-10

Several risk factors for asthma have been identified in infants and young children with recurrent wheeze. However, published literature has reported contradictory findings regarding the underlying immunological mechanisms.This study was designed to assess compare status during first 2 years steroid-naive >or= three episodes of physician-confirmed wheeze (n=50), without clinical developing subsequent (i.e. parental or a personal history eczema and/or two following: wheezing colds, allergic...

10.1111/j.1365-2222.2009.03253.x article EN Clinical & Experimental Allergy 2009-04-29

Minimal/measurable residual disease (MRD) testing by flow cytometry (FC) has been proposed as a potential surrogate clinical endpoint in plasma cell myeloma (PCM) trials. As result, effort gone into standardizing this approach on PCM patients.To assess inter-laboratory variation FC MRD of patients an independent study.A dilution series five stabilized bone marrow samples manufactured to contain 0%, 0.1%, 0.01%, 0.001%, and 0.0001% neoplastic cells (PCs) were tested blind, using standardized...

10.1002/cyto.b.21754 article EN Cytometry Part B Clinical Cytometry 2018-12-19

Abstract Background HLA class I peptide tetramers represent powerful diagnostic tools for detection and monitoring of antigen‐specific CD8 + T cells. The impetus the current multicenter study is critical need to standardize tetramer flow cytometry if it be implemented as a routine assay. Hence, European Working Group on Clinical Cell Analysis set out develop evaluate single‐platform tetramer‐based method that used cytomegalovirus (CMV) antigenic model. Methods Absolute numbers CMV‐specific...

10.1002/cyto.b.20028 article EN Cytometry Part B Clinical Cytometry 2004-10-21

BACKGROUND: Clinical indications for lymphocyte subset enumeration by flow cytometry include monitoring of disease progression and timing therapeutic intervention in infection with human immunodeficiency virus. Until recently international standardisation has not been possible due to a lack suitable stable reference material. METHODS: This study consisted two trials stabilised whole blood preparation. Eleven participants were sent standard protocols staining plus gating strategy asked report...

10.1002/cyto.b.20061 article EN Cytometry Part B Clinical Cytometry 2005-06-22

Early-stage chronic lymphocytic leukemia (CLL) with neurologic involvement is a rare condition and should require careful follow-up. Although no standard protocol exists for this condition, intrathecal chemotherapy, combined systemic chemoimmunotherapy, has been used previously. This case describes the treatment of patient CLL symptomatic compromise central nervous system. Our results suggest that combination radiotherapy, ibrutinib, administered sequentially over 2-year period, led to...

10.1155/2018/7817918 article EN cc-by Case Reports in Hematology 2018-05-27

Clinical cases play a pivotal role in the daily routine of clinical laboratory. The screening and diagnosis different types samples sent to flow cytometry laboratory represent challenge those charge processing, acquiring, analyzing them. fact that we are dealing with biological specimens make them unique and, as all know, many times they do not replicate phenotype entities described literature. According these premises, European Working Group for cell analysis decided promote plenary session...

10.1002/cyto.b.20568 article EN Cytometry Part B Clinical Cytometry 2010-12-03

This year, the European Society for Clinical Cell Analysis (ESCCA) organized its 9th Euroconference on in conjunction with 5th Cytometry Course St. Étienne, France. As September 1, 220 paying participants had signed up 3-day conference and 196 one of four 2-day courses, respectively. For latter, topics were offered from which to choose advance: leukemia; immunophenotyping special samples; immunology; platelets. The organization was similar as previous years, i.e., invited oral presentations...

10.1002/cyto.b.20498 article EN Cytometry Part B Clinical Cytometry 2009-09-30
Coming Soon ...